Plain-English translation of NCT04959201 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining an NMDA-enhancing medication with an antioxidant drug can work better than the NMDA-enhancing medication alone for treating schizophrenia. You would continue taking your regular antipsychotic medication while also receiving the new medication combination (or a placebo). Researchers believe this combination might help reduce symptoms that aren't fully controlled by current treatments.
Schizophrenia involves two different brain chemistry problems: issues with NMDA receptors and oxidative stress (cellular damage). While NMDA-enhancing medications have shown promise, scientists don't yet know if adding an antioxidant drug could make this treatment even more effective.
You likely qualify if…
You likely don't qualify if…
You would keep taking your regular antipsychotic medication unchanged and visit the clinic at weeks 0, 2, 4, 6, 9, and 12 over the 12-week study period. At each visit, your symptoms and any side effects would be checked. You would be randomly assigned to receive either the new medication combination or a placebo (inactive pill) along with the NMDA-enhancing medication. At the beginning and end of the study, you would also complete cognitive testing to assess your thinking and memory.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Taiwan